



THE  
BLADDER CANCER  
COMPANY™

## Photocure ASA: Invitation to presentation of first quarter 2020 financial results

**Oslo, Norway, 30 April 2020: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2020 financial results on Thursday 7 May 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 15:00 CET the same day.**

The investor presentation will be streamed live and be hosted by Daniel Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event.

The quarterly report and presentation will be published at 07:00 CET and will be publicly available at [www.photocure.com](http://www.photocure.com). The streaming event is available through [https://channel.royalcast.com/webcast/hegnaamedia/20200507\\_6/](https://channel.royalcast.com/webcast/hegnaamedia/20200507_6/)

The presentation is scheduled to conclude at 15:45 CET.

Please note that preliminary financial results for the first quarter of 2020 were announced in the trading update of 27 April 2020. The trading update is available in the presentation of the agreement to regain the worldwide rights for Hexvix: <https://newsweb.oslobors.no/message/503877>

**For further information, please contact:**

### **Photocure**

Erik Dahl

CFO

Tel: +47 45055000

Email: [ed@photocure.com](mailto:ed@photocure.com)

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway) Tel: +47 91540000

Email: [geir.bjorlo@corpcom.no](mailto:geir.bjorlo@corpcom.no)

### **About Photocure**

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at [www.photocure.com](http://www.photocure.com), [www.hexvix.com](http://www.hexvix.com), [www.cysview.com](http://www.cysview.com)

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.